Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

KROS - Keros Therapeutics, Inc. Последние новости | Finranks

Home

/

KROS

K

Keros Therapeutics, Inc. (KROS)

NGM – Цена в реальном времени. Валюта: USD

11.65

-0.36 (-3.00%)

При закрытии: May 12, 2026, 4:00 PM EDT

11.85

+0.20 (1.71%)

До открытия: May 13, 2026, 7:01 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros Therapeutics KROS reshaped its financial profile in 2025 by pairing a major licensing transaction with a shift in development responsibilities. The result was a step-change in reported revenue and a meaningful reduction in internal research and development burden.

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

KROS: Is the Discount Book Value a Value Trap?

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

Видео

No Data

There is no data to display

Пресс-релизы

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (“ALS”) within the Healey ALS MyMatch program (“ALS MyMatch”), led by the Sean M.

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025.

Keros Therapeutics Appoints Charles Newton to its Board of Directors

Keros Therapeutics Appoints Charles Newton to its Board of Directors

LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026.